James Tang

San Bruno, CA ***** 650-***-**** ad2w6d@r.postjobfree.com

Associate Scientist/ Scientist I

A highly motivated and result oriented associate scientist/scientist, possessing broad R&D experience in cell biology, molecular biology, in vivo pharmacology, and immunology. Excellent mammalian cell culture, protein purification & characterization, molecular cloning, animal handing and surgical skills and statistical analysis techniques were used for drug discovery, therapy selection, target validation and animal models of diseases. Strong techniques in immunoassay development and data analysis for small molecules and proteins. GMP/GLP trained in product development and in writing method validation reports that are helpful and supportive to preclinical department.

Professional Experience

Pfizer (formerly known as Global Blood Therapeutics, Inc.) August 2015 - February 2024

Associate Scientist/Scientist I, Biology

Set up human progenitor CD34+ cell culture system and use it to screen and characterize hemoglobin inducers.

Establish and validate both absolute and relative qPCR methods for quantification of hemoglobin gene expression.

Validate ELISA assay for hemoglobin quantification in cell lysate samples.

Use FACS analysis to evaluate erythroid maturation and HbF hemoglobin expression.

Validate the drug target by using RNAi technology to knockdown the mRNA expression in human bone marrow CD34+ cells.

Investigate the interaction between a particular protein and DNA to promote HbF production by performing ChIP assay.

Harvest bone marrow from femurs and establish cell culture for characterization of lead compounds.

Run proliferation assay to screen and characterize cancer-killing compounds made by chemistry department.

Evaluate combination therapy with outside chemo compounds in different cancer cell lines.

Run HEMOX analyzer to screen new 3rd generation compounds in whole blood or purified hemoglobin solution.

Characterize lead compounds by sickling assay, red blood cell partition assay and hemoglobin off rate assay.

Evaluate hemoglobin’s oxygen binding affinity induced by GBT compound with measuring Bohr effect and 2,3-DPG effects.

Analyze experiment results by GraphPad Prism and present data at project meetings.

Techniques utilized:

Mammalian cell culture and cell-based assay, progenitor CD34+ cell culture and differentiation, relative quantification and absolute quantification by qPCR assay (Applied Biosystems ViiA7), TaqMan gene expression Cells-to-Ct assay, SYBR green Real-Time PCR assay, RNA and DNA isolation, PBMC purification, flow cytometry (Accuri C6 & Cytek Aurora & FlowJo), ChIP assay, RNA interference assay, ELISA assays and fluorescence-based assays (SpectraMax M5&SoftMax Pro, SPECTROstar Nano, Envision), cell proliferation assay, sickling assay, HEMOX analysis, statistical analysis (Prism).

James Tang ad2w6d@r.postjobfree.com Page 2

Igenica Biotherapeutics, Inc. July 2009 - July 2015

Senior Research Associate, Cell Line Generation

Design and subclone gene of interest into retroviral vector, lentiviral vector, and other expression vectors for stable cell line generation. My work supported the whole company’s anti-tumor monoclonal antibody production.

Transfect mammalian cells to establish transient and stable cell lines for identifying target location.

Antibody variable region DNA sequence analysis for hybridoma identification and selection.

Change antibody Fc DNA sequence and clone into expression vector for antibody isotype switching and specific function attenuation.

Target-expression tumor cell implantation for antibody production, tumor measurement and excision.

Master cell banking and quality control (IMPACT) for antibody producing cell lines before immunization.

Perform flow cytometry analysis (FACS) for target expression and therapeutic antibody selection.

Run SDS-PAGE and Western Blot for analysis of protein samples.

Flow cytometry analysis for ADC treated cells and assess drug candidate’s therapeutic efficacy in vitro.

Extract RNA from endogenous tumor cell lines for gene expression study and target selection. My contribution directly helped at least five target selections.

Design experiment to clone out mouse and cynomolgus monkey target genes from tissue samples for cytotoxicity study. This kind of DNA sequence analysis played a key role in animal study designs.

Run real time PCR (qPCR) for gene expression study and target expression monitor in stable cell lines. The experiment results helped cell line selection.

Design and mutate target protein at different extracellular domains for antibody binding site identification or functional assays.

Optimize expression vector with promoter or resistance gene switching. The vector modification improved target gene expression and cell clone selection.

Techniques utilized:

PCR and real-time PCR (qPCR), In-fusion cloning, Gateway cloning technology, TOPO cloning, design mutagenesis & fusion protein, RNA and DNA isolation, DNA sequence analysis, bacterial transformation, plasmid DNA miniprep and maxiprep, mammalian cell culture, transfection, flow cytometry (Accuri C6 & Macsquant & FlowJo), Western Blot, cell-based assay, animal handling & surgery, tumor cell implantation, ELISA assay (SpectraMax M5&SoftMax Pro, MSD, Luminex), statistical analysis (Prism), fluorescence microscopy.

Metabolex, Inc. November 2003 - February 2009

Research Associate IV, In Vivo Pharmacology

Design and carry out efficacy studies in diabetic animal models for drug screen and therapy selection.

Perform all ELISA assays (insulin, GLP-1, GIP, PYY, Leptin, adiponectin, etc.) for each efficacy study and clamp study.

Perform statistical data analysis (Prism) and responsible for final data interpretation and data presentation at project team meeting.

Cannulate carotid artery and jugular vein in rat for hyperglycemic clamp studies.

Implant the Alzet pump containing testing compounds for long-term efficacy studies.

James Tang ad2w6d@r.postjobfree.com Page 3

Execute hyperglycemic clamp study, OGTT, ITT and incretin study.

Develop high-fat diet or streptozotocin (STZ) treatment induced diabetic mouse models.

Perform necropsy and collect tissues for histopathology study.

Antibody purification and insulin depletion assay development.

Develop and validate DPP4 activity assay and fatty acid synthase activity assay for mechanism of action studies.

Design study protocol and execute in house non-GLP toxicology studies.

Responsible for adopting and validating all kinds of new assay kits used in IVP group and training team members for running assays.

Perform tissue extraction procedure to determine insulin content in pancreas, triglyceride, and glycogen in liver.

Carry out single dose or repeated dose PK experiments for drug metabolism study.

Techniques utilized:

Animal surgery, animal handling, PO, IV, SC, IP dosing, animal bleeding, diabetic animal model development, OGTT and ITT, ELISA and colorimetric assay, MSD assay, Luminex assay, antibody purification and immunoassay development, biopsy and necropsy, insulin and glycogen extraction, statistical analysis by Prism.

Gryphon Therapeutics, Inc. April 2003 - November 2003

Research Scientist I, Formulation

Coordinate efficacy study of Exendin-4-PEG with outside service providers.

Develop peptide mapping method to confirm protein sequence and to determine impurities.

Develop HPLC methods to evaluate different formulations of Exendin-4-PEG.

FibroGen, Inc. January 1999 - April 2003

Research Scientist I, Collagen Department

Develop hemorrhage animal models for testing hemostatic effect of tissue sealant.

Establish animal implantation model for osteogenesis study and safety study.

Produce GMP-complied recombinant human collagen injectable gel for phase I clinical trial.

Develop HPLC methods and protein assays to validate tissue sealant formulations.

Characterize recombinant human collagen by HPLC, Western blot, SDS-PAGE, and host cell protein assays.

Shaman Pharmaceuticals, Inc. January 1996 - January 1998

Senior Research Associate, Biology

Execute efficacy studies in diabetic or insulin resistant animal models for drug discovery.

Develop streptozotocin (STZ) induced diabetic mouse model and diet induced obese insulin resistant mouse model for drug screen program.

Run ELISA and colorimetric assays (insulin, glucose, triglyceride, FFA, etc.) to evaluate anti-diabetic effects.

Conduct exercise plus drug combination therapies on db/db mice for treatment optimization.

Perform OGTT and ITT to assess insulin resistance in drug-treated animal models.

James Tang ad2w6d@r.postjobfree.com Page 4

Megabios Corp May 1995 - December 1995

Senior Research Associate, Life Science,

Perform in vivo gene therapy study to evaluate the drug delivery routes. Responsibilities were to dose animal, observe animal health, harvest tissue, and run protein assay.

Idetek, Inc. November 1994 - May 1995

Senior Research Associate, R&D department

Develop diagnostic immunoassay kits to detect antibiotic residues in agricultural products. Responsibilities were to purify antibody, determine antibody concentration, coat plate, and execute assay.

Peninsula Laboratories, Inc. March 1989 - November 1994

Senior Research Associate, Immunology

Conjugate peptide to carrier protein and inject to rabbit for antibody production.

Purify antibody and characterize antibody for assay development.

Develop ELISA, EIA and RIA research kits for pharmaceutical industry.

Write development reports, validation reports and assay protocol.

Chongqing Institute of Oncology, China July 1985 - April 1988

Orthopedist, Surgery Department

Perform human orthopedic surgical procedures and conduct chemotherapy for osteosarcoma patients.

Education

MS, Biomedical Laboratory Science 1998

San Francisco State University

BS, Surgery 1985

Chongqing Medical University, China

References Upon request

Publications

Kobina Dufu,1 Carsten Alt,1 Steven Strutt,1 James Partridge,1 James Tang,1 Vincent Siu,1 Hilary Liao-Zou,1 Peter Rademacher,1 Alexander T. Williams,2 Cynthia R. Muller,2 Xin Geng,1 Mira Patel Pochron,1 Annie Nguyen Dang,1 Pedro Cabrales,2 Zhe Li,1 Donna Oksenberg,1 Brian E. Cathers1, GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. BJHaem, Feb. 2023

Nokelainen M, Yang C, Hillas P, Tang J, Balan J, Polarek J and Spiro R. A recombinant human collagen matrix. J. Biomed. Mat. Res. Nov. 2003

Yang C, Hillas P, Tang J, Balan J, Notbohm H, Polarek J. A recombinant human collagen III-based hemostat. Mat. Res. Nov 2003

Tang J, Reed MJ. Exercise adds to metformin and acarbose efficacy in db/db mice. Metabolism. 2001 Sep;50(9):1049-53

James Tang ad2w6d@r.postjobfree.com Page 5

Abstracts:

Kobina Dufu, PhD; Carsten Alt, MSc, PhD; Steven Strutt, PhD; James Tang; Hilary Liao-Zou; Yue Yuan; Brian E. Cathers, PhD; Donna Oksenberg, PhD. GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model. The 62nd ASH Annual Meeting and Exposition, San Diego, 2020.

Xin Geng, PhD1; Radu Mihaila1; Yue Yuan1; Steven Strutt, PhD1; Jörg Benz2; James Tang1; Christina Mayer, PharmD1; Donna Oksenberg, PhD1. Inclacumab, A Fully Human Anti-P-selectin Antibody, Directly Binds to PSGL-1 Binding Region and Demonstrates Robust and Durable Inhibition of Cell Adhesion. The 62nd ASH Annual Meeting and Exposition, San Diego, 2020.

Zhang F, Clemens E, Gregoire F, Wilson M, Udove J, Tang J, Gelling R and Gustafson T. Metaglidasen, a novel selective peroxisome proliferators-activated receptor-γ modulator, preserves pancreatic islet structure and function in db/db mice. 2006 ADA Meeting, Washington DC, June 2006

Yang C, Hillas P, Baez J, Nokelainen M, Balan J, Tang J, Spiro R, Polarek J. The application of recombinant human collagen in tissue engineering. BioDrugs, 2004 vol:18 (2) pp:103-119.

Yang C, Tang J, Hillas P, Balan J, Folz A, Polarek J. Formulation of tissue sealant with rhc type III collagen. 29th Annual Meeting of the society of Biomaterial, Reno, April 2003

Nokelainen M, Yang C, Hillas P, Tang J, Balan J, Polarek J and Spiro R. Recombinant human collagens in tissue repair. 29th Annual Meeting of the society of Biomaterial, Reno, April 2003

Tang J. Exercise improves metformin and acarbose action in db/db mice. 13th ADA annual North California Symposium, San Francisco, December, 1997.

Contact this candidate